DBVT · DBV Technologies S.A. · Executive Compensation
$9.94
-0.17 (-1.68%)
At close · Nov 4
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Oct 28, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our management concluded that our recurring losses from operations, existing unrestricted cash, and cash equivalents raise substantial doubt about our ability to continue as a going concern for the next twelve months after issuance of our financial statements included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Oct 28, 2026
Market Cap
$624.64M
Shares
62.84M
Volume · Nov 4
378.31K
Avg daily vol (3M)
368.25K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Daniel Tassé | Chief Executive Officer and Director | $1,472,146 |
| Pharis Mohideen | Chief Medical Officer | $820,762 |
| Virginie Boucinha | Chief Financial Officer | $458,450 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Daniel Tassé | Chief Executive Officer and Director | $2,440,486 |
| Pharis Mohideen | Chief Medical Officer | $1,279,518 |
| Sébastien Robitaille | Former Chief Executive Officer | $344,286 |
| Virginie Boucinha | Chief Financial Officer | $234,630 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Daniel Tassé | Chief Executive Officer and Director | $2,787,640 |
| Pharis Mohideen | Chief Medical Officer | $1,076,807 |
| Sébastien Robitaille | Former Chief Executive Officer | $501,628 |
| Virginie Boucinha | Chief Financial Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Daniel Tassé | Chief Executive Officer and Director | $2,430,966 |
| Pharis Mohideen | Chief Medical Officer | $1,196,778 |
| Sébastien Robitaille | Chief Financial Officer | $612,091 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Daniel Tassé | Chief Executive Officer and Director | $2,062,135 |
| Pharis Mohideen | Chief Medical Officer | $1,032,851 |
| Sébastien Robitaille | Chief Financial Officer | $509,778 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Sébastien Robitaille | Chief Financial Officer | $724,403 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Daniel Soland | Board of Directors | Resigned | 2025-10-30 |
| Philina Lee | member of the Compensation Committee | Appointed | 2025-10-30 |
| Philina Lee | Board of Directors | Appointed | 2025-10-30 |
| Daniel Soland | member of its Board of Directors | Resigned | 2025-09-18 |
| Virginie Boucinha | Chief Financial Officer | Appointed | 2023-10-16 |
| Daniele Guyot-Caparros | Board | Appointed | 2022-10-04 |
| Timothy E. Morris | Chairperson of the Audit Committee | Appointed | 2022-10-04 |
| Viviane Monges | Board | Resigned | 2022-10-04 |
Leadership
- Daniel Tassé CEO, Board Member
- Michel de Rosen Chairman
- Virginie Boucinha CFO, Chief Accounting Officer
- Adora Ndu Board Member
- Daniele Guyot-Caparros Board Member
- Julie O’Neill Board Member
- Maïlys Ferrère Board Member
- Michael J. Goller Board Member
- Philina Lee Board Member
- Ravi M. Rao Board Member
- Timothy E. Morris Board Member
Key facts
CIK
1613780
CUSIP
23306J309
13F (30d)
13 filings
11 filers
Visit website
Investor relations